ABSTRACT. A two-year old male Welsh Corgi was referred for persistent thrombocytosis and occasional seizure. Hematological findings indicated marked thrombocytosis, eosinophilia, basophilia and moderate anemia. Bone marrow examination revealed marked megakaryocytic hyperplasia with morphologic abnormality. A diagnosis of essential thrombocythemia was made and the treatment was initiated with combination chemotherapy and maintained by prednisolone and busulfan. The dog successfully achieved complete remission on 100 days after initial presentation and has been good in health without chemotherapy since then. KEY WORDS: busulfan, essential thrombocythemia, seizure.
Essential thrombocythemia (ET) is one of myeloproliferative disorders characterized by the proliferation of a pluripotent hematopoietic stem cell, leading to expansion of the megakaryocytic compartment in bone marrow, and the excessive and presumably autonomous production of structurally and functionally abnormal platelets [10, 16] . The clinical signs in humans with ET are occasionally related to microvascular thrombosis or bleeding [13, 14] . Although a number of human patients have contracted ET, limited cases have been reported in dogs so far. Canine cases of ET rarely showed symptoms of thrombosis or hemorrhage and clinical sings of them are nonspecific [1, 3, 5, 6, 11, 16, 18] . Hematological findings in dogs with ET indicated persistent marked thrombocytosis with morphologic abnormality and hypercoagulation and bone marrow examination revealed marked megakaryocytic hyperplasia without blastocytosis [1, 3, 5, 6, 11, [16] [17] [18] . Diagnosis of ET involves ruling out other causes of thrombocytosis and treatment has not yet been established. This report describes clinicopathological features and therapy in a dog with ET.
A two-year old intact male Welsh Corgi was referred for 3 months history of persistent thrombocytosis and seizure in case of exercising and exciting. Mixed vaccination and heartworm prophylaxis were performed every year. The dog had mild weight loss, pale mucous membranes and rectal temperature of 39.5°C. All other aspects of physical examination including auscultatory sound, pulse pressure and neurological examination were unremarkable. Hematological findings were characterized by nonregenerative anemia (packed cell volume [PCV], 22%), marked thrombocytosis (3,940 × 10 3 /µl) and leukocytosis (46,400/ µl) including eosinophilia (7, 190 /µl), basophilia (10,440/µl) and unclassified cells (6,730/µl) ( Table 1) . Abnormal thrombocyte morphology including hypogranular platelets, giant platelets and micromegakaryocytes were observed on the peripheral blood smear (Fig. 1) . 2 BSA/day, IV, day 75) was performed. Although platelet count remained increasing, seizure was not found and general condition was improved since day 10. On day 60, platelet count was decreasing and later PCV was increasing. Since platelet count and PCV were within normal ranges on day 100, maintenance protocol was initiated with prednisolone (0.25-0.5 mg/kg/day, day 152-650) and busulfan (6-40 mg/ m 2 BSA/day, PO, day 114-513). The dog suffered no severe side effects, with the exception of mild myelosuppression, during the chemotherapy. Administration of busulfan was discontinued on day 513 and the dog has been clinically normal without chemotherapy since then.
The diagnosis of ET in humans and dogs has been made by the exclusion of all other causes of thrombocytosis including reactive thrombocytosis and thrombocytosis associated to other myeloproliferative disorders [3, 14, 16] . Reactive thrombocytosis has rarely resulted in platelet counts recorded over 1,000 × 10 3 /µl and is often impermanent [5, 16] . The present case had prominent (3,940 × 10 3 / µl) and persistent (approximate 5 months) thrombocytosis and did not have any other histories and diseases inducing thrombocytosis. It was reported that some dogs with the other chronic myeloproliferative disorders and myelodysplastic syndromes occasionally showed thrombocytosis [8, 17] . In the case of acute megakaryoblastic leukemia (M7), pancytopenia has been frequently observed and thrombocytosis has been rarely seen [3, 17] . The hematological findings including bone marrow examination in the dog reported here indicated neither erythroid and myeloid hyperplasia, multiple lineage dysplasia, nor proliferation of blast cells.
Additionally, eosinophilia, basophilia, elevated VB12 concentration and splenomegaly were revealed in this case and might be subsidiary features of chronic myeloproliferative disorders [4, 16] . Especially eosinophilia and basophilia are considered to be due to abnormal proliferation of hematopoietic precursors. These findings supported to make a diagnosis of ET.
The clinical signs in human with ET are vague and incidentally related to microvascular thrombosis or bleeding [13, 14] . In some cases, neurological symptoms occurred by cerebral hemorrhage and thrombotic infraction. These symptoms have not been reported in dogs with ET. In the present case, transient seizure was occurred in case of excitement and exercise and was not observed since administration of dipyridamole. Dipyridamole is one of anticoagulant agents preventing aggregation and adhesion of platelets by inhibition of platelet phosphodiesterase and activation of adenyl cyclase [7, 19] . Since the symptom was improved after anticoagulant therapy in spite of elevated platelet count in the dog, the anticoagulant therapy was supposed to be effective to prevent clinical signs associated with ET in dogs.
In humans, chemotherapy of ET has been performed by using alkylating agents or hydroxyurea [2] . It was reported that dogs with ET had good responses to chemotherapy with hydroxyurea or combination chemotherapy [1, 16, 18] . However, there are limited literatures and information on canine ET and fundamental treatment strategy for canine ET has not yet been established. Combination chemotherapy has rarely been performed in the other chronic myeloproliferative diseases. The chemotherapy in this case was initiated with chlorambucil that was known to have less harmful side effects because the dog was in poor condition. However, marked thrombocytosis remained, and so other chemotherapeutic agents, generally used in canine hematopoietic malignancy, were included. Finally, this case was induced remission with combination chemotherapy and then well maintained with prednisolone and busulfan without severe side effects. Although busulfan is generally used to treat ET in humans [2] , it has not been reported canine ET treated with busulfan. The chemotherapy using busulfan had been performed in dogs with acute myeloblastic leukemia, chronic myeloid leukemia and basophilic leukemia [9, 12, 15] . Since the present case was maintained with busulfan, it was supposed that busulfan was effective for maintenance therapy in dogs with ET. 
